Torus Biosystems company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

torus.bio

Founded Year

2019

Stage

Series A | Alive

Total Raised

$28.89M

Last Raised

$25.21M | 1 yr ago

About Torus Biosystems

Torus Biosystems performs testing of DNA for scientific and medical research purposes.

Torus Biosystems Headquarter Location

125 CambridgePark Drive

Cambridge, Massachusetts, 02140,

United States

603-785-8646

ESPs containing Torus Biosystems

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Medical Devices Tech

Point-of-care (POC) testing refers to diagnostic lab tests that can be performed rapidly, reliably, and easily at or near the point of care. Starting with a biological sample, POC tests detect or quantify certain analytes — such as infectious agents, cardiac markers, and blood glucose — to inform clinical decision making.

Torus Biosystems named as Challenger among 15 other companies, including BD, Accellix, and Genalyte.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Torus Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Torus Biosystems is included in 4 Expert Collections, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

M

Medical Devices

8,684 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

3,095 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

H

Health IT

7,900 items

Latest Torus Biosystems News

Study Published in Nature Biomedical Engineering Demonstrates the Unique Capabilities of Torus Biosystems Donut PCR System

Jul 6, 2021

07/06/2021 | 06:02am EDT Message : Precision syndromic testing at the point of care is within reach Torus Biosystems , Inc., a point of care molecular diagnostics company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, today announced the publication of performance results for its Donut PCR system. The full manuscript, titled Highly multiplexed rapid DNA detection with single-nucleotide specificity via convective PCR in a portable device, is published in Nature Biomedical Engineering . Study authors, including Dmitriy Khodakov, Ph.D. and David Zhang, Ph.D., reported on the development of a novel qPCR-based detection platform that can precisely detect and quantify multiplex DNA/RNA targets simultaneously in a rapid and easy to operate point-of-care system. “Detection of specific nucleic acid sequences is the key for delivering precision medicine,” said Dr. Khodakov, co-inventor and Principle Scientist at Torus Biosystems, “We noted that with molecular technologies to date, the greater the multiplexing capabilities, the slower the time to result. Our objective was to eliminate this trade-off by rapidly delivering high multiplex results as well as accurate quantitation and reliable recognition of single-nucleotide differences.” The publication describes the authors’ design and performance validation of a portable device employing a toroidal (i.e., donut-shaped) PCR system that achieves high multiplex target detection with single-nucleotide discrimination and precise result quantitation in less than 30 minutes. Performance of the prototype donut PCR system was validated through a series of experiments involving the detection of microbial agents. The study authors developed a multiplex identification panel for 15 species of bacteria, including the most common ESKAPE pathogens. The system correctly identified targeted bacterial strains with high specificity in test and mixed samples of clinical isolates. Other system performance highlights include demonstration of an analytical dynamic range of at least 4 logs, accurate quantitation, robust signal-to-noise ratios, single-base resolution of similar targets, ability to discriminate related SNP targets, and rapid detection of high multiplexing targets (30 targets). "Historically, highly multiplexed DNA detection has been difficult to achieve in a rapid turnaround setting," said David Zhang, Ph.D., Associate Professor of Bioengineering at Rice University, co-founder of Torus Biosystems, and senior author of the study. "The Donut PCR system, which serves as the basis for Torus's Synestia™ platform, allows scalable, rapid, accurate, and affordable detection of many pathogens, enabling syndromic testing." About Torus Biosystems Torus Biosystems , a spinout from the Harvard Wyss Institute for Biologically Inspired Engineering, is on a mission to transform patient lives by delivering breakthrough innovations in infectious disease diagnostics. The Company is currently developing syndromic testing solutions based on the integration of novel technologies, including qPCR and microarray technologies, that enable rapid, quantitative, and highly multiplexed detection of microbial pathogens, resistance genes and host immune-response markers that ultimately lead to improved patient outcomes. Learn more about how Torus Bio can help clinicians deliver better patient care, combat antibiotic resistance, and promote antimicrobial stewardship by visiting the website at www.torus.bio and connecting on social media @Twitter and @LinkedIn . View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005188/en/ © Business Wire 2021

Torus Biosystems Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Torus Biosystems Rank

  • When was Torus Biosystems founded?

    Torus Biosystems was founded in 2019.

  • Where is Torus Biosystems's headquarters?

    Torus Biosystems's headquarters is located at 125 CambridgePark Drive, Cambridge.

  • What is Torus Biosystems's latest funding round?

    Torus Biosystems's latest funding round is Series A.

  • How much did Torus Biosystems raise?

    Torus Biosystems raised a total of $28.89M.

  • Who are the investors of Torus Biosystems?

    Investors of Torus Biosystems include Technology Crossover Ventures and Northpond Ventures.

  • Who are Torus Biosystems's competitors?

    Competitors of Torus Biosystems include Visby Medical, Baebies, Cardea Bio, MeMed, Accellix, Inflammatix, Oxford Nanopore Technologies, LumiraDx, Cue Health, Roche Holding and 22 more.

You May Also Like

A
Accellix

Accellix develops fully automated, cost-effective, actionable cell-based analysis, 24/7 at the point of need, to a broad range of users. Its Accellix single-use cartridge analysis system provides results in less than 30 minutes, requires minimal training, and does not require users to deal with biological reagents, sample preparation, and complex data analysis.

Visby Medical Logo
Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.

L
Lumos Diagnostics

Lumos Diagnostics provides rapid, cost effective, and complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to help healthcare professionals more accurately diagnose and manage diseases and medical conditions. Lumos provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures, and will commercialize a suite of Lumos-branded POC tests.

MeMed Logo
MeMed

MeMed is a med-tech and bio-convergence firm that researches, develops, and commercializes diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes.

Ellume Logo
Ellume

Ellume is a digital diagnostics company that develops and commercializes connected products for healthcare professionals and consumers. The company has developed a new biosensor technology that features unique optoelectronics and biologics.

Weavr Health Logo
Weavr Health

Weavr Health is dedicated to connecting people to health by simplifying sample collection and processing for healthcare.The Velvet device is designed so anyone, anywhere can easily collect high-quality samples without a phlebotomist. The Velvet device offers a smooth experience of blood self-collection for patients. It leverages a similar experience to traditional glucose testing, which >25% of people have experienced. Each device arrives with all that is needed to collect, package and ship quality samples to the lab for a convenient experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.